PPARA and cancer: Furthermore, the PPAR agonist pioglitazone has also been studied for its ability to prevent radiation‐induced cognitive decline in non‐diabetic patients undergoing radiotherapy in a Phase I clinical trial (Clinicaltrials.gov: NCT01151670),138 suggesting huge potentials of PPAR agonist as an adjuvant when combined with other therapies for improving the effectiveness and reducing the side effects of cancer treatments.